двойно- слепи, плацебо контролирани изпитвания с Nespo с общ брой пациенти - 2 112 (1 200 на Nespo, 912 на плацебо).
Adverse reactions were determined based on pooled data from seven randomised, double-blind, placebo-controlled studies of Nespo with a total of 2112 patients (Nespo 1200, placebo 912).